KRT‑232, A FIRST‑IN‑CLASS, MURINE DOUBLE MINUTE 2 INHIBITOR (MDM2I), FOR MYELOFIBROSIS (MF) RELAPSED OR REFRACTORY (R/R) TO JANUS‑ASSOCIATED KINASE INHIBITOR (JAKI) TREATMENT (TX)
Author(s): ,
Haifa Kathrin Al-Ali
Affiliations:
Department of Hematology and Medical Oncology,University Hospital of Halle,Halle,Germany
,
Regina García Delgado
Affiliations:
Hospital Universitario Virgen de la Victoria,Málaga,Spain
,
Andrzej Lange
Affiliations:
L. Hirszfeld Institute of Immunology and Experimental Therapy/Lower Silesian Center for Cellular Transplantation with National Bone Marrow Donors Registry,Wroclaw,Poland
,
Andrzej Pluta
Affiliations:
Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im. Ks. B. Markiewicza,Brzozów,Poland
,
Donal P. McLornan
Affiliations:
Guy's and Saint Thomas' NHS Foundation Trust,London,United Kingdom
,
Pankit Vachhani
Affiliations:
University of Alabama at Birmingham,Birmingham,United States
,
Gandhi Laurent Damaj
Affiliations:
CHU Caen,Caen,France
,
Philipp J. Jost
Affiliations:
Technical University of Munich,Munich,Germany
,
László Rejtő
Affiliations:
Josa András Teaching Hospital,Nyíregyháza,Hungary
,
Marek Hus
Affiliations:
Medical University in Lublin,Lublin,Poland
,
Sebastian Grosicki
Affiliations:
Silesian Medical University,Katowice,Poland
,
Juan Carlos Hernández-Boluda
Affiliations:
Hospital Clínico Universitario,Valencia,Spain
,
Joanne Ewing
Affiliations:
University Hospitals Birmingham NHS Foundation Trust,Birmingham,United Kingdom
,
Jesse McGreivy
Affiliations:
Kartos Therapeutics, Inc.,Redwood City,United States
,
Wayne P. Rothbaum
Affiliations:
Kartos Therapeutics, Inc.,Redwood City,United States
,
Hope Qamoos
Affiliations:
Kartos Therapeutics, Inc.,Redwood City,United States
,
Jean-Jacques Kiladjian
Affiliations:
Hopital Saint-Louis,Paris,France
Srdan Verstovsek
Affiliations:
The University of Texas MD Anderson Cancer Center,Houston,United States
EHA Library. Kathrin Al-Ali H. 06/12/20; 295035; S215
Haifa Kathrin Al-Ali
Haifa Kathrin Al-Ali
Contributions
Abstract

Abstract: S215

Type: Oral Presentation

Presentation during EHA25: All oral abstract presentations will be made available on the on-demand Virtual Congress platform as of Friday, June 12 at 08:30 CEST and will be accessible until October 15, 2020.

Session title: Novel therapies and pitfalls in MPN

Background
More than 70% of MF patients (pts) treated with ruxolitinib (Rux) discontinue tx within 5 years (Verstovsek et al. J Hematol Oncol. 2017). The prognosis for these pts is poor with a reported median (med) overall survival of 14 months (Kuykendall et al. Ann Hematol. 2018). In MF pts, MDM2, a key negative regulator of the tumor suppressor protein p53, is overexpressed in circulating CD34+ hematopoietic stem/progenitor cells (Lu et al. Blood. 2017). This provides the rationale to test KRT‑232, a potent, orally available small molecule inhibitor of MDM2 in MF patients.

Aims
This is an ongoing single‑arm, 2‑part, open‑label, global phase 2 study (NCT03662126) in pts with MF who are R/R to prior JAKi tx (intolerant pts are excluded). Part A evaluated safety and efficacy to determine the dose and schedule for Part B.

Methods
Eligible pts were aged ≥18 years with ECOG PS ≤2 and had intermediate or high-risk disease (per Dynamic International Prognostic System [DIPSS] scoring). Pts were randomly assigned to 1 of 3 Arms: KRT-232 120 mg (A1) or 240 mg (A2) daily (qd) on days (d) 1-7 of 21-d cycles or 240 mg qd (A3) on d 1-7 of 28-d cycle. Rux washout was not required. The primary endpoint was spleen volume reduction (SVR) ≥35% at week (wk) 24 by MRI/CT (central review). Key secondary endpoints were safety and tolerability and improvement of total symptom score (TSS) of ≥50% at wk 24 and 48 by modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN‑SAF) v2.0.

Results
As of 21 Jan 2020 and with a med follow-up of 5.1 months, 82 pts were enrolled across 64 sites in North America and Europe, representing a heterogenous and heavily pre-treated group of MF pts (med prior tx = 2 and med time on prior Rux = 15 months). 98% were p53WT and clinical characteristics were similar among Arms (Figure).  A3 pts who crossed wk 12 or 24 or discontinued drug for any reason, best SVR35 was 16% (4/25); 9 pts in A3 remain on tx and have not crossed wk 24. Among the 44% of A3 pts who were on Rux at baseline scan (BLS), the reported mean change in spleen volume (BLS to wk 12) was (+)3% vs. (-)18% for pts not on Rux at BLS. Pts with a BLS within 7d of first KRT-232 dose had a more pronounced mean SVR at wk 12 vs pts who had a BLS >7 days prior to first dose, (-)21%, (-)4%; respectively. Of pts on the 120 mg dose (A1) who crossed wk 12 or 24, none achieved SVR ≥35% (Figure). Treatment-emergent AEs (TEAEs), regardless of causality, were reported in 98% of patients (51% Grade 3; 24% Grade 4). The most common TEAEs were diarrhea (62%), thrombocytopenia (45%), nausea (38%), anemia (29%), vomiting (21%), abdominal pain (20%), neutropenia (18%), and asthenia (16%). Grade 5 TEAEs occurred in 5 pts; 3 were deemed unrelated to KRT-232.

Conclusion
KRT-232 demonstrates a dose-dependent relationship for safety and efficacy and shows promising activity and tolerability in poor prognosis R/R MF pts. Of note, magnitude of SVR may have been confounded by a lack of Rux washout and the timing of BLS relative to initiation of KRT-232. This is the first clinical proof-of-concept highlighting the important role of MDM2i for the treatment of R/R MF. Recommended dose and schedule for Part B is KRT-232 240 mg d 1-7/28-d cycle.

Session topic: 16. Myeloproliferative neoplasms - Clinical

Keyword(s): Myelofibrosis

Abstract: S215

Type: Oral Presentation

Presentation during EHA25: All oral abstract presentations will be made available on the on-demand Virtual Congress platform as of Friday, June 12 at 08:30 CEST and will be accessible until October 15, 2020.

Session title: Novel therapies and pitfalls in MPN

Background
More than 70% of MF patients (pts) treated with ruxolitinib (Rux) discontinue tx within 5 years (Verstovsek et al. J Hematol Oncol. 2017). The prognosis for these pts is poor with a reported median (med) overall survival of 14 months (Kuykendall et al. Ann Hematol. 2018). In MF pts, MDM2, a key negative regulator of the tumor suppressor protein p53, is overexpressed in circulating CD34+ hematopoietic stem/progenitor cells (Lu et al. Blood. 2017). This provides the rationale to test KRT‑232, a potent, orally available small molecule inhibitor of MDM2 in MF patients.

Aims
This is an ongoing single‑arm, 2‑part, open‑label, global phase 2 study (NCT03662126) in pts with MF who are R/R to prior JAKi tx (intolerant pts are excluded). Part A evaluated safety and efficacy to determine the dose and schedule for Part B.

Methods
Eligible pts were aged ≥18 years with ECOG PS ≤2 and had intermediate or high-risk disease (per Dynamic International Prognostic System [DIPSS] scoring). Pts were randomly assigned to 1 of 3 Arms: KRT-232 120 mg (A1) or 240 mg (A2) daily (qd) on days (d) 1-7 of 21-d cycles or 240 mg qd (A3) on d 1-7 of 28-d cycle. Rux washout was not required. The primary endpoint was spleen volume reduction (SVR) ≥35% at week (wk) 24 by MRI/CT (central review). Key secondary endpoints were safety and tolerability and improvement of total symptom score (TSS) of ≥50% at wk 24 and 48 by modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN‑SAF) v2.0.

Results
As of 21 Jan 2020 and with a med follow-up of 5.1 months, 82 pts were enrolled across 64 sites in North America and Europe, representing a heterogenous and heavily pre-treated group of MF pts (med prior tx = 2 and med time on prior Rux = 15 months). 98% were p53WT and clinical characteristics were similar among Arms (Figure).  A3 pts who crossed wk 12 or 24 or discontinued drug for any reason, best SVR35 was 16% (4/25); 9 pts in A3 remain on tx and have not crossed wk 24. Among the 44% of A3 pts who were on Rux at baseline scan (BLS), the reported mean change in spleen volume (BLS to wk 12) was (+)3% vs. (-)18% for pts not on Rux at BLS. Pts with a BLS within 7d of first KRT-232 dose had a more pronounced mean SVR at wk 12 vs pts who had a BLS >7 days prior to first dose, (-)21%, (-)4%; respectively. Of pts on the 120 mg dose (A1) who crossed wk 12 or 24, none achieved SVR ≥35% (Figure). Treatment-emergent AEs (TEAEs), regardless of causality, were reported in 98% of patients (51% Grade 3; 24% Grade 4). The most common TEAEs were diarrhea (62%), thrombocytopenia (45%), nausea (38%), anemia (29%), vomiting (21%), abdominal pain (20%), neutropenia (18%), and asthenia (16%). Grade 5 TEAEs occurred in 5 pts; 3 were deemed unrelated to KRT-232.

Conclusion
KRT-232 demonstrates a dose-dependent relationship for safety and efficacy and shows promising activity and tolerability in poor prognosis R/R MF pts. Of note, magnitude of SVR may have been confounded by a lack of Rux washout and the timing of BLS relative to initiation of KRT-232. This is the first clinical proof-of-concept highlighting the important role of MDM2i for the treatment of R/R MF. Recommended dose and schedule for Part B is KRT-232 240 mg d 1-7/28-d cycle.

Session topic: 16. Myeloproliferative neoplasms - Clinical

Keyword(s): Myelofibrosis

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies